EIP Pharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.eippharma.com
Clinical Trials
19
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
- Conditions
- Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 20
- Registration Number
- NCT07033481
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
- Conditions
- Moderate to Severe Acute Ischaemic StrokeIschaemic Stroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 90
- Registration Number
- NCT06987643
- Locations
- 🇦🇺
Campbelltown Hospital, Campbelltown, New South Wales, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Sunshine Coast University Hospital, Birtinya, Queensland, Australia
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 25
- Registration Number
- NCT06815965
- Locations
- 🇫🇷
Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive, Paris, France
🇫🇷Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg), Strasbourg, France
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 159
- Registration Number
- NCT05869669
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Banner Alzheimer's Institute - Edson Family Lewy Body Dementia Center, Tucson, Arizona, United States
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 91
- Registration Number
- NCT04001517
- Locations
- 🇺🇸
University of California San Diego (UCSD), La Jolla, California, United States
🇺🇸Pacific Neuroscience Institute, Santa Monica, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
- Prev
- 1
- 2
- Next